Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Marsh

Showing results (621-630 of 654) with videos related to

Pageof 66
Sort By:
Bioorganic & Medicinal Chemistry|June 11, 2008
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2005
Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonistsAnil Vasudevan, Matthew J LaMarche, Christopher Blackburn, et al.
Journal of Medicinal Chemistry|February 4, 2005
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moietiesArthur Gomtsyan, Erol K Bayburt, Robert G Schmidt, et al.
Journal of Medicinal Chemistry|September 25, 2008
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligandsRobert J Altenbach, Ronald M Adair, Brian M Bettencourt, et al.
Bioorganic & Medicinal Chemistry|October 23, 2010
Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic painMarc J C Scanio, Lei Shi, Irene Drizin, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseH L Sham, D J Kempf, A Molla, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|May 3, 2005
5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitorsMark A Matulenko, Chih-Hung Lee, Meiqun Jiang, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2023
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of CryptosporidiosisMatthew A Hulverson, Ryan Choi, Deborah A Schaefer, et al.
Pageof 66

Showing results (621-630 of 654) with videos related to

Sort By:
Pageof 66
Bioorganic & Medicinal Chemistry|June 11, 2008
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancerThomas D Penning, Gui-Dong Zhu, Viraj B Gandhi, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2005
Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonistsAnil Vasudevan, Matthew J LaMarche, Christopher Blackburn, et al.
Journal of Medicinal Chemistry|February 4, 2005
Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moietiesArthur Gomtsyan, Erol K Bayburt, Robert G Schmidt, et al.
Journal of Medicinal Chemistry|September 25, 2008
Structure-activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligandsRobert J Altenbach, Ronald M Adair, Brian M Bettencourt, et al.
Bioorganic & Medicinal Chemistry|October 23, 2010
Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic painMarc J C Scanio, Lei Shi, Irene Drizin, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseH L Sham, D J Kempf, A Molla, et al.
Journal of Medicinal Chemistry|May 26, 2007
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotensionGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Bioorganic & Medicinal Chemistry|May 3, 2005
5-(3-Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine: structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitorsMark A Matulenko, Chih-Hung Lee, Meiqun Jiang, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2023
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of CryptosporidiosisMatthew A Hulverson, Ryan Choi, Deborah A Schaefer, et al.
Pageof 66